AR039672A1 - Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat) - Google Patents
Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat)Info
- Publication number
- AR039672A1 AR039672A1 ARP030102120A ARP030102120A AR039672A1 AR 039672 A1 AR039672 A1 AR 039672A1 AR P030102120 A ARP030102120 A AR P030102120A AR P030102120 A ARP030102120 A AR P030102120A AR 039672 A1 AR039672 A1 AR 039672A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- hydrogen
- ibat
- benzotiazepina
- dipeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Su uso como inhibidores del transporte ileal del ácido biliar (IBAT) para el tratamiento de la hiperlipidemia. Procesos para su fabricación y composiciones farmacéuticas que los contienen. Reivindicación 1: Un compuesto, caracterizado porque responde a la fórmula (1) donde: R1 y R2 se seleccionan independientemente entre alquilo C1-4; R3 es hidrógeno, hidroxi o halo; R4 es alquilo C1-4 opcionalmente sustituido por hidroxi, metoxi y metilS(O)a donde a es 0-2; R5 es hidroxi o HOC(O)CH(R6)NH-; R6 se seleccionan entre hidrógeno y alquilo C1-3 opcionalmente sustituido por hidroxi, metoxi y metilS(O)a donde a es 0-2; o una sal aceptable para uso farmacéutico, solvato, solvato de dicha sal o una prodroga del mismo; con la salvedad de que cuando R1 y R2 son ambos butilo, R5 es hidroxi y R4 es metiltiometilo, metilsulfinilmetilo, 2-metiltioetilo, hidroximetilo, metoximetilo; R3 no es hidrógeno; y con la salvedad de que cuando R1 y R2 son ambos butilo, R5 es HOC(O)CH(R')NH-, R6 es hidroximetilo y R4 es hidroximetilo; R3 no es hidrógeno.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0213669.5A GB0213669D0 (en) | 2002-06-14 | 2002-06-14 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039672A1 true AR039672A1 (es) | 2005-03-09 |
Family
ID=9938564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030102120A AR039672A1 (es) | 2002-06-14 | 2003-06-13 | Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat) |
Country Status (25)
Country | Link |
---|---|
US (1) | US7192947B2 (es) |
EP (1) | EP1515984B1 (es) |
JP (1) | JP4423191B2 (es) |
KR (1) | KR20050010514A (es) |
CN (1) | CN1659182A (es) |
AR (1) | AR039672A1 (es) |
AT (1) | ATE424407T1 (es) |
AU (1) | AU2003240079B2 (es) |
BR (1) | BR0311628A (es) |
CA (1) | CA2489463A1 (es) |
DE (1) | DE60326451D1 (es) |
ES (1) | ES2321826T3 (es) |
GB (1) | GB0213669D0 (es) |
IS (1) | IS7597A (es) |
MX (1) | MXPA04012603A (es) |
MY (1) | MY134270A (es) |
NO (1) | NO20045099L (es) |
NZ (1) | NZ537122A (es) |
PL (1) | PL372626A1 (es) |
RU (1) | RU2315772C2 (es) |
SA (1) | SA03240217B1 (es) |
TW (1) | TWI282790B (es) |
UY (1) | UY27846A1 (es) |
WO (1) | WO2003106482A1 (es) |
ZA (1) | ZA200409860B (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
CN1582151A (zh) | 2001-09-08 | 2005-02-16 | 阿斯特拉曾尼卡有限公司 | 用于治疗高脂血症、具有回肠胆汁酸转运(ibat)抑制活性的苯并硫氮杂䓬和苯并硫杂二氮杂䓬衍生物 |
SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
EP1517883B8 (en) * | 2002-06-20 | 2008-05-21 | AstraZeneca AB | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
EP1689378B1 (en) | 2003-12-02 | 2009-04-15 | Schwarz Pharma Ag | Novel use of peptide compounds for treating central neuropathic pain |
EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
AR057828A1 (es) * | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
EA019757B1 (ru) | 2006-06-15 | 2014-06-30 | ЮСиБи ФАРМА ГМБХ | Фармацевтическая композиция с синергетическим противосудорожным эффектом |
RU2480453C2 (ru) | 2007-03-08 | 2013-04-27 | Альбирео Аб | Новые соединения |
SI2637668T1 (sl) | 2010-11-08 | 2016-11-30 | Albiero Ab | IBAT inhibitorji za zdravljenje jetrnih bolezni |
BR112013011249A2 (pt) * | 2010-11-08 | 2017-11-14 | Albireo Ab | inibidores de ibat para tratamento de distúrbios metabólicos e condições relacionadas |
CA2815698C (en) * | 2010-11-08 | 2019-04-30 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
CN107375932B (zh) | 2011-10-28 | 2021-12-21 | 夏尔人类遗传性治疗公司 | 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂 |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
KR20220082931A (ko) | 2014-06-25 | 2022-06-17 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
CN108601744B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
JP6954927B2 (ja) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
CN110996915B (zh) | 2017-08-09 | 2023-10-03 | 阿尔比里奥公司 | 考来烯胺丸粒、口服考来烯胺制剂及其用途 |
CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
US10428109B1 (en) | 2018-03-09 | 2019-10-01 | Elobix Ab | Process for the preparation of 1,5-benzothiazepine compounds |
BR112020017353A2 (pt) * | 2018-03-09 | 2020-12-15 | Elobix Ab | Processos para a preparação de um composto e de uma modificação de cristal iv de elobixibat. |
TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2019245449A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
AU2020218908A1 (en) | 2019-02-06 | 2021-08-26 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
WO2020161216A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
AR120683A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2021110883A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
CR20220315A (es) | 2019-12-04 | 2022-10-26 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar |
JP2023537285A (ja) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
EP4255565A1 (en) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
US20230338392A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
US20240067617A1 (en) | 2022-07-05 | 2024-02-29 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4900757A (en) | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
JPH05186357A (ja) | 1991-12-31 | 1993-07-27 | Shigeo Ochi | 飲食物消化分解産物吸収抑制手段 |
GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
ZA941003B (en) | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
WO1996008484A1 (en) | 1994-09-13 | 1996-03-21 | Monsanto Company | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
CN1515567A (zh) | 1996-03-11 | 2004-07-28 | G.D.ɪ����˾ | 具有作为回肠胆汁酸转运和牛磺胆酸盐吸收抑制剂活性的新的苯并噻庚因 |
GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
HUP0002395A3 (en) | 1997-03-11 | 2002-12-28 | G D Searle & Co Chicago | Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors |
ES2198613T3 (es) | 1997-03-14 | 2004-02-01 | Aventis Pharma Deutschland Gmbh | 1,4-benzotiazepina-1,1-dioxidos hipolipidemicos. |
AUPO763197A0 (en) | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
DK1042314T3 (da) | 1997-12-19 | 2003-07-14 | Searle & Co | Fremgangsmåde til fremstilling af enantiomert berigede tetrahydrobenzothiepinoxider |
GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
DK1140190T3 (da) | 1998-12-23 | 2002-12-23 | Searle Llc | Kombinationer af ileumgaldesyretransport-inhibitorer og galdesyre-sekvestreringsmidler til cardiovaskulære indikatorer |
IL143944A0 (en) | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations for cardiovascular indications |
BR9916486A (pt) | 1998-12-23 | 2002-02-05 | Searle Llc | Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares |
NZ512537A (en) | 1998-12-23 | 2003-11-28 | G | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
PL348581A1 (en) | 1998-12-23 | 2002-06-03 | Searle Llc | Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
KR20020000139A (ko) | 1999-02-12 | 2002-01-04 | 추후제출 | 회장 담즙산 수송 및 타우로콜산염 흡수의 억제제로서의활성을 보유하는 신규한 1,2-벤조티아제핀 |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
US6287609B1 (en) | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
CA2400021A1 (en) | 2000-02-18 | 2001-08-23 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
SE0000772D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
WO2001068637A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Method for the preparation of tetrahydrobenzothiepines |
WO2001068096A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
WO2002053548A1 (en) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Benzothiazepine derivatives |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
CN1582151A (zh) * | 2001-09-08 | 2005-02-16 | 阿斯特拉曾尼卡有限公司 | 用于治疗高脂血症、具有回肠胆汁酸转运(ibat)抑制活性的苯并硫氮杂䓬和苯并硫杂二氮杂䓬衍生物 |
GB0201850D0 (en) * | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
-
2002
- 2002-06-14 GB GBGB0213669.5A patent/GB0213669D0/en not_active Ceased
-
2003
- 2003-06-10 NZ NZ537122A patent/NZ537122A/en unknown
- 2003-06-10 US US10/518,010 patent/US7192947B2/en not_active Expired - Fee Related
- 2003-06-10 DE DE60326451T patent/DE60326451D1/de not_active Expired - Lifetime
- 2003-06-10 KR KR10-2004-7020341A patent/KR20050010514A/ko not_active Application Discontinuation
- 2003-06-10 BR BR0311628-0A patent/BR0311628A/pt not_active IP Right Cessation
- 2003-06-10 ES ES03732693T patent/ES2321826T3/es not_active Expired - Lifetime
- 2003-06-10 WO PCT/GB2003/002499 patent/WO2003106482A1/en active Application Filing
- 2003-06-10 RU RU2005100836/04A patent/RU2315772C2/ru not_active IP Right Cessation
- 2003-06-10 PL PL03372626A patent/PL372626A1/xx not_active Application Discontinuation
- 2003-06-10 MX MXPA04012603A patent/MXPA04012603A/es active IP Right Grant
- 2003-06-10 CN CN038137372A patent/CN1659182A/zh active Pending
- 2003-06-10 EP EP03732693A patent/EP1515984B1/en not_active Expired - Lifetime
- 2003-06-10 CA CA002489463A patent/CA2489463A1/en not_active Abandoned
- 2003-06-10 JP JP2004513313A patent/JP4423191B2/ja not_active Expired - Fee Related
- 2003-06-10 AT AT03732693T patent/ATE424407T1/de not_active IP Right Cessation
- 2003-06-10 AU AU2003240079A patent/AU2003240079B2/en not_active Ceased
- 2003-06-12 TW TW092115986A patent/TWI282790B/zh not_active IP Right Cessation
- 2003-06-12 MY MYPI20032191A patent/MY134270A/en unknown
- 2003-06-12 UY UY27846A patent/UY27846A1/es unknown
- 2003-06-13 AR ARP030102120A patent/AR039672A1/es not_active Application Discontinuation
- 2003-07-27 SA SA03240217A patent/SA03240217B1/ar unknown
-
2004
- 2004-11-23 NO NO20045099A patent/NO20045099L/no not_active Application Discontinuation
- 2004-12-06 ZA ZA200409860A patent/ZA200409860B/en unknown
- 2004-12-15 IS IS7597A patent/IS7597A/is unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200409860B (en) | 2005-10-19 |
SA03240217B1 (ar) | 2007-10-29 |
ES2321826T3 (es) | 2009-06-12 |
RU2315772C2 (ru) | 2008-01-27 |
CA2489463A1 (en) | 2003-12-24 |
US20050222120A1 (en) | 2005-10-06 |
MXPA04012603A (es) | 2005-03-23 |
NO20045099L (no) | 2005-01-06 |
MY134270A (en) | 2007-11-30 |
AU2003240079B2 (en) | 2007-11-15 |
CN1659182A (zh) | 2005-08-24 |
GB0213669D0 (en) | 2002-07-24 |
UY27846A1 (es) | 2003-12-31 |
NZ537122A (en) | 2006-11-30 |
KR20050010514A (ko) | 2005-01-27 |
EP1515984A1 (en) | 2005-03-23 |
WO2003106482A1 (en) | 2003-12-24 |
EP1515984B1 (en) | 2009-03-04 |
JP4423191B2 (ja) | 2010-03-03 |
TWI282790B (en) | 2007-06-21 |
TW200400182A (en) | 2004-01-01 |
RU2005100836A (ru) | 2005-09-10 |
ATE424407T1 (de) | 2009-03-15 |
BR0311628A (pt) | 2005-03-08 |
IS7597A (is) | 2004-12-15 |
JP2006506328A (ja) | 2006-02-23 |
AU2003240079A1 (en) | 2003-12-31 |
US7192947B2 (en) | 2007-03-20 |
PL372626A1 (en) | 2005-07-25 |
DE60326451D1 (de) | 2009-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039672A1 (es) | Dipeptido, derivado de benzotiazepina. inhibidor del transporte ileal de acidos biliares (ibat) | |
IS6852A (is) | Efnasambönd | |
AR082825A2 (es) | Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios | |
AR063707A1 (es) | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden. | |
ECSP099371A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
UY27437A1 (es) | Compuestos químicos | |
ATE438634T1 (de) | Benzothiazepinderivate | |
NO20040945L (no) | Benzotiepin ileal gallesyre transport inhibitorer | |
PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
AR063706A1 (es) | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. | |
EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
GEP20125456B (en) | Azetidines as mek inhibitors for the treatment of proliferative diseases | |
CY1113395T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη | |
BRPI0507312A (pt) | derivados de quinolina para uso como inibidores micobacterianos | |
ECSP066383A (es) | Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias | |
EA200802390A1 (ru) | Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их | |
EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
DE602006021539D1 (en) | Morpholine als 5ht2c-agonisten | |
AR047382A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
AR049274A1 (es) | Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2 | |
EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
PE20090880A1 (es) | Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa | |
CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |